Dr Regueiro, professor and chair of the Department of Gastroenterology, Hepatology, and Nutrition at the Cleveland Clinic, spoke to the Advances in Inflammatory Disease regional meeting on April 16 about the potential and promise of a new therapeutic agent, S1P modulators.
According to Dermot McGovern, MD, gastroenterologists are already practicing precision medicine in caring for patients with inflammatory bowel disease. Read on for more of his presentation at the Advances in Inflammatory Bowel Diseases virtual regional meeting April 16.
In this podcast Dr Chiorean, director of the IBD Center for Excellence at Virginia Mason Medical Center in Seattle, Washington, reviews his presentation at the recent Advances in Inflammatory Bowel Diseases virtual meeting about the risks and reasons for de-escalating or stopping therapy for IBD.
PIANO is a landmark study and registry developed to follow the effects of treatment for inflammatory bowel disease among women during pregnancy and their children following birth. Principal investigator Uma Mahadevan, MD, from the University of California San Francisco, answered some questions about this important research project.
Dr Ha, from Cedars-Sinai in Los Angeles, reviews her presentation from the Advances in Inflammatory Bowel Disease regional meeting April 16 on how to help young patients with IBD make a smooth transition from pediatric to adult care.
Dr Chiorean, from the Virginia Mason Medical Center in Seattle, discusses his presentation at the Advances in Inflammatory Bowel Diseases 2021 regional meeting on April 16 on how to use Janus kinase inhibitors in managing inflammatory bowel disease.
William Sandborn, MD, from the University of California San Diego, the use of algorithms based on the results of meta-analyses of trials to position first- and second-line therapeutic agents to achieve the best outcomes in caring for patients with inflammatory bowel disease.
At the Advances in Inflammatory Bowel Diseases virtual regional meeting April 16, Uma Mahadevan, MD, highlighted the safety and efficacy of ustekinumab for IBD care, and noted that new interleukin inhibitors are soon to come.
In this video Dr Melmed, from Cedars-Sinai in Los Angeles, discusses the increased risk of C. difficile among patients with inflammatory bowel disease and the range of therapies available for treating this infection, which he presented at the Advances in Inflammatory Bowel Diseases regional meeting April 16.
Dr Melmed, from Cedars-Sinai in Los Angeles, previews the panel session on positioning therapies in IBD that he will chair at the Advances in Inflammatory Bowel Diseases 2021 regional meeting April 16.